國立虎尾科技大學 |

Baseline Skin Cytokine Profiles Determined by RNA in Situ Hybridization Correlate with Response to Dupilumab in Patients with Eczematous Dermatitis.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Baseline Skin Cytokine Profiles Determined by RNA in Situ Hybridization Correlate with Response to Dupilumab in Patients with Eczematous Dermatitis./
Author:	Singh, Katelyn.
Description:	1 online resource (47 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 85-02, Section: B.
Contained By:	Dissertations Abstracts International85-02B.
Subject:	Medicine. -
Online resource:	click for full text (PQDT)
ISBN:	9798379965068

Baseline Skin Cytokine Profiles Determined by RNA in Situ Hybridization Correlate with Response to Dupilumab in Patients with Eczematous Dermatitis.
Singh, Katelyn.

Baseline Skin Cytokine Profiles Determined by RNA in Situ Hybridization Correlate with Response to Dupilumab in Patients with Eczematous Dermatitis. - 1 online resource (47 pages)

Source: Dissertations Abstracts International, Volume: 85-02, Section: B.

Thesis (M.D.)--Yale University, 2023.

Includes bibliographical references

Dupilumab, a monoclonal antibody that inhibits IL4 and IL13, has revolutionized the treatment of atopic dermatitis (AD). However, not all patients respond optimally, and this may relate to underlying molecular heterogeneity. Yet, clinically useful and accessible methods to assess such heterogeneity have not been developed. Additionally, As the number of targeted medications continues to expand, the choice of which specific therapy to initiate in any individual patient will become increasingly difficult. Currently, there are no biomarkers that can be used to guide treatment selection in common inflammatory diseases such as atopic dermatitis (AD) and psoriasis. This study aims to determine whether cytokine staining and/or histologic features correlate with clinical response to dupilumab in patients with eczematous dermatitis. We retrospectively analyzed biopsies from 61 patients with eczematous dermatitis treated with dupilumab. RNA in situ hybridization (RISH) was used to measure markers of Type 2 (IL4, IL13), Type 1 (IFNG) and Type 3 (IL17A, IL17F, IL22) inflammation. Histologic features were also assessed. Patterns were compared among complete (n=16), partial (n=37), and non-responders (n=8) to dupilumab. We found that increased IL13 expression was associated with optimal response to dupilumab. In contrast, non-responders tended to express less IL13 and relatively greater levels of Type 1 and 3 cytokines. Histologically, non-responders tended to have increased levels of spongiosis, acanthosis, and epidermal inflammation. Overall, these findings suggest that cytokine profiles determined by RISH may aid in treatment selection for eczematous disorders and imply that tissue-based biomarkers may be useful in the personalization of the treatment of inflammatory skin disease.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798379965068Subjects--Topical Terms:

644133
Medicine.
Subjects--Index Terms:

Atopic dermatitisIndex Terms--Genre/Form:

554714
Electronic books.

Baseline Skin Cytokine Profiles Determined by RNA in Situ Hybridization Correlate with Response to Dupilumab in Patients with Eczematous Dermatitis.
LDR:03181ntm a22003857 4500 001 1149291
005 20241015112502.5
006 m o d
007 cr bn ---uuuuu
008 250605s2023 xx obm 000 0 eng d
020 $a 9798379965068
035 $a (MiAaPQ)AAI30310980
035 $a AAI30310980
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Singh, Katelyn. $3 1475462
245 1 0 $a Baseline Skin Cytokine Profiles Determined by RNA in Situ Hybridization Correlate with Response to Dupilumab in Patients with Eczematous Dermatitis.
264 0 $c 2023
300 $a 1 online resource (47 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-02, Section: B.
500 $a Advisor: Damsky, William.
502 $a Thesis (M.D.)--Yale University, 2023.
504 $a Includes bibliographical references
520 $a Dupilumab, a monoclonal antibody that inhibits IL4 and IL13, has revolutionized the treatment of atopic dermatitis (AD). However, not all patients respond optimally, and this may relate to underlying molecular heterogeneity. Yet, clinically useful and accessible methods to assess such heterogeneity have not been developed. Additionally, As the number of targeted medications continues to expand, the choice of which specific therapy to initiate in any individual patient will become increasingly difficult. Currently, there are no biomarkers that can be used to guide treatment selection in common inflammatory diseases such as atopic dermatitis (AD) and psoriasis. This study aims to determine whether cytokine staining and/or histologic features correlate with clinical response to dupilumab in patients with eczematous dermatitis. We retrospectively analyzed biopsies from 61 patients with eczematous dermatitis treated with dupilumab. RNA in situ hybridization (RISH) was used to measure markers of Type 2 (IL4, IL13), Type 1 (IFNG) and Type 3 (IL17A, IL17F, IL22) inflammation. Histologic features were also assessed. Patterns were compared among complete (n=16), partial (n=37), and non-responders (n=8) to dupilumab. We found that increased IL13 expression was associated with optimal response to dupilumab. In contrast, non-responders tended to express less IL13 and relatively greater levels of Type 1 and 3 cytokines. Histologically, non-responders tended to have increased levels of spongiosis, acanthosis, and epidermal inflammation. Overall, these findings suggest that cytokine profiles determined by RISH may aid in treatment selection for eczematous disorders and imply that tissue-based biomarkers may be useful in the personalization of the treatment of inflammatory skin disease.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Medicine. $3 644133
650 4 $a Immunology. $3 592892
653 $a Atopic dermatitis
653 $a Cytokines
653 $a Dupilumab
653 $a Eczema
653 $a RNA
655 7 $a Electronic books. $2 local $3 554714
690 $a 0564
690 $a 0982
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Yale University. $b Yale School of Medicine. $3 1464899
773 0 $t Dissertations Abstracts International $g 85-02B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30310980 $z click for full text (PQDT)